As previously reported, Piper Sandler downgraded Alignment Healthcare to Neutral from Overweight with a price target of $6, down from $12, following mixed Q4 results where membership and revenue beat, but adjusted EBITDA missed the low end of guidance and consensus estimates. The firm appreciates Alignment’s competitive advantages, but relative positioning does not extinguish absolute risk. New member mix shift, utilization volatility, and v28 challenge the assumptions underlying the company’s 2024 MBR guide and may jeopardize its adjusted EBITDA breakeven timeline.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on ALHC:
- Alignment Healthcare reports Q4 EPS (25c), consensus (22c)
- Alignment Healthcare Reports Fourth Quarter and Full-Year 2023 Results; Provides Full-Year 2024 Financial Guidance
- ALHC Earnings Report this Week: Is It a Buy, Ahead of Earnings?
- Alignment Healthcare to Announce Fourth Quarter and Full-Year 2023 Financial Results and Host Conference Call Tuesday, Feb. 27, 2024
- Alignment Healthcare price target lowered to $8.50 from $10.50 at Stephens
